Semaglutide at higher doses (2.4 mg weekly) has shown the most robust evidence for NASH resolution in clinical trials, achieving resolution in 59% of patients
The Cleveland Clinic study includes nearly 8,000 patients who discontinued semaglutide and tirzepatide, common GLP-1 medications
Quick Answer: GLP-1 receptor agonists are not licensed or supported by clinical evidence for rheumatoid arthritis treatment in the UK, and microdosing remains experimental without established safety or efficacy data
Whats great about PlushCare is the fact that it uses local licensed and regulated pharmacies
We serve patients across Orange County, Riverside, San Diego, San Bernardino, and the Inland Empire, making access to treatment simpler and more manageable